Welcome to our dedicated page for SGRX news (Ticker: SGRX), a resource for investors and traders seeking the latest updates and insights on SGRX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SGRX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SGRX's position in the market.
SANGRIX (SGRX) sold 3,000,000 Dogecoin on September 7, 2026, generating approximately US$267,665 in gross proceeds to support working capital and its transition toward AI computing infrastructure.
The sale was executed in two transactions of 1,500,000 DOGE each at a weighted average price of about US$0.089221667 per DOGE, before fees. DOGE’s USD daily closing price rose about 10.7% over the seven days ended September 6, 2026, based on CoinGecko data, which is given as market context. SANGRIX plans to use net proceeds for general working capital and planned AI infrastructure expenditures and may consider further DOGE sales depending on market conditions, liquidity needs and capital allocation priorities.